Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7604787 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL11942791 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL10941216 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL4326524 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL10936372 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL4335363 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL10941081 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL271637 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT | |
| SCHEMBL427388 | 1.00 | — | — | |
| SCHEMBL9085134 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ATHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102015632-A | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD | 2011-04-13 | — | — | CN | claimed |
| US-12034122-B2 | Electrolytic solution for lithium-ion secondary battery and lithium-ion secondary battery | MURATA MANUFACTURING CO., LTD. (JP) | 2024-07-09 | — | — | US | disclosed |
| EP-3806220-A1 | ELECTROLYTE FOR LITHIUM-ION SECONDARY CELL, AND LITHIUM-ION SECONDARY CELL | Murata Manufacturing Co., Ltd. (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20210066756-A1 | ELECTROLYTIC SOLUTION FOR LITHIUM-ION SECONDARY BATTERY AND LITHIUM-ION SECONDARY BATTERY | MURATA MANUFACTURING CO., LTD. (JP) | 2021-03-04 | — | — | US | disclosed |
| CN-102015632-A | Synthesis of a PEG-6 moiety from commercial low-cost chemicals | GE HEALTHCARE LTD | 2011-04-13 | — | — | CN | disclosed |
| US-20090305949-A1 | GLYCOSYLATED SPECIFICITY EXCHANGER | TRIPEP AB (SE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009141486-A1 | NEOGLYCOLIPIDS, AGGREGATES THEREOF WITH CARBON NANOTUBES, METHOD FOR OBTAINING SAME AND USE THEREOF | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009122408-A1 | STABLE C - (sup3) - CYCLOMETALATED PINCER COMPLEXES, THEIR PREPARATION AND USE AS CATALYSTS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD (IL) | 2009-10-08 | — | — | WO | disclosed |
| EP-0765304-B1 | METHOD OF PREPARING ALPHA-METHOXYIMINOCARBOXYLIC ACID METHYLAMIDES, AND INTERMEDIATES USED IN THE METHOD | BASF AG (DE) | 1999-08-11 | — | — | EP | disclosed |
| US-5856560-A | REACTING ACYL CYANIDE BENZENE COMPOUND WITH AN ALCOHOL; THEN AN HYDROXYLAMINE; METHYLATION | BASF AKTIENGESELLSCHAFT (DE) | 1999-01-05 | — | — | US | disclosed |
| EP-0765304-A1 | METHOD OF PREPARING ALPHA-METHOXYIMINOCARBOXYLIC ACID METHYLAMIDES, AND INTERMEDIATES USED IN THE METHOD | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-02 | — | — | EP | disclosed |
| US-5512207-A | Azaaromatic compounds, process for their preparation, and their use in liquid-crystalline mixtures | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-30 | — | — | US | disclosed |
| WO-1995034526-A1 | METHOD OF PREPARING α-METHOXYIMINOCARBOXYLIC ACID METHYLAMIDES, AND INTERMEDIATES USED IN THE METHOD | BASF AKTIENGESELLSCHAFT (DE) | 1995-12-21 | — | — | WO | disclosed |
| US-4196089-A | MAGNESIUM OXIDE, CELLOSOLVE ETHER, MAGNESIUM COMPLEX | WITCO CHEMICAL CORPORATION (US) | 1980-04-01 | — | — | US | disclosed |
| US-4000258-A | INSECTICIDES, ALCOHOLS, POLYOXYETHYLENE (PROPYLENE) GLYCOL | SANDOZ, INC. (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090305949-A1 | GLYCOSYLATED SPECIFICITY EXCHANGER | SLC17A5, ASGR1, SLC2A1 | ALDH1A1 2150/4885MEN1 2459/4885KMT2A 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.